OncRef

Clinical Trial: NCT04305834

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:City of Hope Medical Center
Information Provided By:City of Hope Medical Center
Last Update Posted:2026-10-16

Study Overview

Brief Summary

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

Official Title

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Conditions

Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Intervention / Treatment

  • Drug: Abemaciclib
  • Other: Questionnaire Administration

Other Study ID Numbers

  • 19206
  • NCI-2019-08847
  • 19206
  • P30CA033572

Start Date (Actual)

2020-06-05

Primary Completion Date (Estimated)

2027-05-21

Study Completion Date (Estimated)

2027-05-21

Enrollment (Estimated)

43

Study Type

Interventional

Phase

Phase 2